/ricerca/ansaen/search.shtml?any=
Show less

Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

New ReiThera vaccine safe, response peak at 4 wks

New ReiThera vaccine safe, response peak at 4 wks

Italy aiming for vaccine independence says Arcuri

ROME, 05 January 2021, 13:26

Redazione ANSA

ANSACheck

- ALL RIGHTS RESERVED

-     ALL RIGHTS RESERVED
- ALL RIGHTS RESERVED

The new COVID vaccine being developed by Rome biotech company ReiThera is safe, a Spallanzani infectious disease hospital official said on Tuesday.
    Giuseppe Ippolito, scientific director at Italy's premier infectious disease hospital, was speaking at the presentation of the results of Phase One of testing of the GRAd-CoV2 vaccine made by ReiThera, which is based at Castel Romano on the outskirts of the Italian capital.
    Ippolito said "we enrolled 100 people and 45 were vaccinated with different doses and all arrived at the end for the safety assessment: the vaccine did not have any serious adverse effect in the first 28 days from the vaccination, a better result compared to Moderna and Pfizer which had undesired effects.
    "The peak of production of antibodies remains constant at four weeks and the vaccine is single dose".
    The new vaccine developed anti-bodies in 92.5% of those tested, Ippolito added.
    ReiThera President Antonella Folgore said the company was aiming to produce 100 million doses of vaccine per year.
    He said the vaccine was stable at a temperature of between two and eight degrees Celsius.
    Italy's COVID commissioner, Domenico Arcuri, said that "with ReiThera Italy is aiming for vaccine independence".
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Share

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.